Clinical Trial Update: Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease [Phase 4]

View source ↗

Summary

Phase 4 results update on the inhaled corticosteroid/long-acting beta-agonist combination Fluticasone Propionate/Salmeterol Diskus 250/50 evaluating exercise en…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone Propionate/Salmeterol Diskus 250/50 (fluticasone propionate; salmeterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2011-12-21